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ABSTRACT 
Nearly 40% of new drug candidates exhibit low solubility in water, which is a challenge in development of optimum oral solid 
dosage form in terms of formulation design and bioavailability of new pharmaceutical products. Many strategies have been used to 
overcome these problems either by means of modifying the solubility or maintaining the drug in dissolved form throughout gastric 
transit time. Much attention has focused on lipid solutions, emulsions and emulsion pre-concentrates, which can be prepared as 
physically stable formulations suitable for encapsulation of such poorly soluble drugs. Recently, self-micro emulsifying drug 
delivery systems (SMEDDS) especially have attracted increasing interest primarily because  these are physically stable, easy to 
manufacture, can be filled in soft gelatin capsules and then will generate a drug containing micro-emulsion with a large surface area 
upon dispersion in the gastrointestinal tract. The emulsions will further facilitate the absorption of the drug due via intestinal 
lymphatic pathway and by partitioning of drug into the aqueous phase of intestinal fluids. In the present review, an overview of 
SMEDDS as a key technology for formulating lipophilic drugs and various factors that potentially affect the oral bioavailability of 
such drugs are presented. 
Keywords: Low solubility, Oral bioavailability, Self-micro emulsion, Intestinal lymphatic pathway. 
_______________________________________________________________________________________________
1. INTRODUCTION 
Various techniques are used to enhance oral 
bioavailability of poorly water soluble drugs
1, 2, 3
. Oral 
route has been the major route of drug delivery for the 
chronic treatment of many diseases as it offers a high 
degree of patient compliance. However, oral delivery of 
50% of the drug compounds is hampered because of the 
high lipophilicity of the drug itself.  Nearly 40% of new 
drug candidates exhibit low solubility in water, which is 
a challenge in development of optimum oral solid 
dosage form in terms of formulation design and 
bioavailability of new pharmaceutical products. Many 
strategies have been used to overcome these problems 
either by means of modifying the solubility or 
maintaining the drug in dissolved form throughout 
gastric transit time 
4, 5
. These strategies may include the 
use of surfactants, cyclodextrins, micronization, 
liquisolid techniques
6
, salt formation, pH change, nano 
size delivery
7
, solid dispersions
8,9
 and permeation 
enhancers and 
10
, 
11
.  
Much attention has focused on lipid solutions, emulsions 
and emulsion preconcentrates, which can be prepared as 
physically stable formulations suitable for encapsulation 
of such poorly soluble drugs. Emulsion systems are 
associated with their own set of complexities, including 
stability and manufacturing problems associated with 
their commercial production. Self-emulsification 
systems are one formulation technique that can be a 
fitting answer to such problems
12
. 
Maurya et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2017; 7(3):55-65                                     
ISSN: 2250-1177                                                                                [56]                                                                             CODEN (USA): JDDTAO 
Among the lipid-based systems, Self-emulsifying drug 
delivery systems (SEDDS) is a promising strategy to 
improve the bioavailability of poorly water-soluble 
compounds. SEDDS are isotropic mixtures of drug, 
lipids and surfactants, usually with one or more 
hydrophilic co-solvents or co-emulsifiers 
13
. Upon mild 
agitation followed by dilution with aqueous media, these 
systems can form fine (oil in water) emulsion 
instantaneously. The size of the droplet formed is 
between 100 and 300 nm while self-micro-emulsifying 
drug delivery systems (SMEDDS) form transparent 
micro-emulsions with a droplet size of less than 50 nm 
14
. 
 
Figure 1: The general strategy of formulating SMEDDS 
and their subsequent conversion to micro-emulsion 
In self emulsifying formulations, the formed emulsion 
increases membrane permeability as a result of 
surfactant presence and enhances lymphatic absorption 
(lymphatic transport) due to medium and long chain oils. 
These factors may contribute significantly to the better 
performance of the formulations
15, 16, 17, 18
. 
Recently, SMEDDS especially have attracted increasing 
interest primarily because  SMEDDS are physically 
stable, easy to manufacture, can be filled in soft gelatin 
capsules and then will generate a drug containing micro-
emulsion with a large surface area upon dispersion in the 
gastrointestinal tract. The emulsions will further 
facilitate the absorption of the drug due to a faster 
digestion by gastrointestinal enzymes and subsequent 
transfer to mixed micelles or possible absorption directly 
from the emulsion particle, by partitioning of drug into 
the aqueous phase of intestinal fluids.
19
 Herein, an 
overview of SMEDDS as a key technology for 
formulating lipophilic drugs and increasing their oral 
bioavailability is presented. 
2. PHYSICO-CHEMICAL ASPECTS OF 
SMEDDS  
2.1 Formulation/ Composition of SMEDDS 
The formulation generally consists of drug, oily vehicle, 
surfactant, co-surfactant and even co-solvents. The basic 
principle of this system is its ability to form fine oil-in-
water (o/w) micro-emulsions under gentle agitation 
following dilution by aqueous phases (ie, the digestive 
motility of the stomach and intestine provide the 
agitation required for self-emulsification in vivo in the 
lumen of the gut). 
20
 This spontaneous formation of an 
emulsion in the gastrointestinal tract presents the drug in 
a solubilized form, and the small size of the formed 
droplet provides a large interfacial surface area for drug 
absorption. 
21
 Apart from solubilization, the presence of 
lipid in the formulation further helps improve 
bioavailability by affecting the drug absorption. 
22
 
Selection of a suitable self-emulsifying formulation 
depends upon the assessment of (1) physicochemical 
properties of the drug, such as pKa, polarity and 
solubility in various components (2) physicochemical 
nature of oily phase, surfactant and co-surfactant (3) the 
area of the self-emulsifying region as obtained in the 
phase diagram, (4) the ratio of the components, 
especially oil to surfactant ratio and (5) the droplet size 
distribution of the resultant emulsion following self-
emulsification. 
23
 
2.1.1 Selection of drug for SMEDDS  
It is important to know that the drug of interest can also 
have significant impact on the various aspects of 
SMEDDS, such as phase behavior and micro-emulsion 
droplet size. Various physicochemical properties of the 
drug, such as pKa, log P, molecular structure and 
weight, presence of ionizable groups and the quantity 
have considerable effects on the performance of 
SMEDDS. Drugs those have low therapeutic dose are 
ideal drug candidates for SMEDDS. 
14
 
One of the primary challenges in designing of oral 
formulation is maintaining drug solubility within the 
G.I.T. and, in particular, maximizing drug solubility 
within the prime absorptive site of the gut 
24
. Drugs 
which are administered at very high dose are not suitable 
for SMEDDS unless they have good solubilization in at 
least one of the excipients of SMEDDS, preferably 
lipophillic phase. The drug must be physically and 
chemically stable in the formulation and the drug release 
pattern must remain constant during the shelf life of the 
SMEDDS formulation. These systems can help in 
solving the under-mentioned problems of all the 
categories of BCS class drugs, as depicted in Table 1.
Table 1: Application of SMEDDS in various BCS class drugs 
25
 
BCS class  Aqueous 
Solubility 
Membrane 
permeability 
Problems 
Class I High High Enzymatic degradation, gut wall efflux 
Class II Low High Solubilization and bioavailability 
Class III High Low Enzymatic degradation, gut wall efflux and bioavailability 
Class IV Low Low Solubilization, enzymatic degradation, gut wall efflux and bioavailability 
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2.1.2 Selection of Excipients for SMEDDS 
The excipients should be chosen from the list of 
generally regarded as safe “GRAS” excipients published 
by USFDA. Good understanding of the characteristics 
of excipients and their performance in formulations are 
the necessary requirements for successful formulation 
development. In order to formulate a successful 
SMEDDS for maximum therapeutic effect, due 
consideration must be given to following factors; 
 Physicochemical properties of the drug as well as 
excipients  
 Potential for drug excipients interaction 
 Physiological factors that promote or inhibit the 
bioavailability 
 Biopharmaceutical factors like as regulatory status, 
solubilization capacity, miscibility, physical state of 
the excipients at room temp. 
 Regulatory aspects of excipients 
 The temperature at which self-emulsification occurs 
When formulating SMEDDS, drugs have to be 
incorporated into an appropriate mixture of excipients; 
therefore formulation development commonly starts 
with excipients selection. As there are many lipid-based 
substances that can be used for formulating SMEDDS, 
some general criteria for excipients selection were 
introduced in order to save time and cut costs.  
During preliminary selection studies, a few excipients 
are identified as possibly appropriate for further research 
owing to their safety, drug solubility and stability in 
excipients, and some other characteristics. Initial 
selection of promising excipients is then followed by 
construction of phase diagrams to identify suitable 
mixing ratios for homogeneous formulations, being just 
as crucial as sufficient solubilization capacity for the 
drug to be incorporated. Once candidate formulations 
are proposed, the drug-loaded systems are subjected to 
in vitro dispersion and digestion tests to predict the fate 
of the drug in the GIT. 
The in vivo behavior of the formulation can be 
interpreted easily by lipid formulation classification 
system (LFCS). With reference to the physico-chemical 
properties of specific drugs, the most suitable 
formulation can be identified through LFCS. Table 2 
shows the various classes of LFCS. Most of the 
marketed products are Type III systems, which are 
diverse with a wide range of oil and water-soluble 
substances. Hence, this group has been further divided 
into Type IIIA (oils) and Type IIIB (water-soluble) 
based on the proportion of oils and water-soluble 
substances
5,22.
 
Table 2: The lipid formulation classification system
 5, 26
 
 Type I Type II Type III A Type III B Type IV 
C
o
m
p
o
si
ti
o
n
 
Oils 100 % 40–80% 40–80 % <20%  0% 
Water-insoluble 
surfactants (HLB < 12) 
0% 20-60% 0% 0% 0-20% 
Water-soluble 
surfactants (HLB > 12) 
0% 0% 20–40% 20–50% 30–80% 
Hydrophilic co-solvents 
(e.g. PEG, propylene 
glycol, transcutol) 
0% 0% 0–40% 20–50% 0–50% 
Particle size Coarse 100-250  100–250 50–100  <50 
Characteristics Non-dispersing Emulsion 
(SEDDS) 
SEDDS/ 
SMEDDS 
formed with 
water-soluble 
components 
SEDDS/ 
SMEDDS 
formed with 
water-soluble 
components 
and low oil 
content 
Disperses 
typically to 
form a 
micellar 
solution 
Digestibility Requires 
digestion 
Will be 
digested 
Digestion may 
not be necessary 
Digestion may 
not be 
necessary 
Limited 
digestion 
Advantages GRAS status; 
simple; 
excellent 
capsule 
compatibility 
 
Unlikely to 
lose solvent 
capacity on 
dispersion 
Clear or almost 
clear dispersion. 
Absorption 
without digestion 
Clear 
dispersion. 
Absorption 
without 
digestion 
 
Good solvent 
capacity for 
many drugs; 
disperse to 
micellar 
solution 
Disadvantages Poor solvent 
capacity 
(unless drug is 
highly 
lipophilic) 
 
Turbid o/w 
dispersion 
Possible loss of 
solvent capacity 
on dispersion. 
Less easily 
digested 
 
Likely loss of 
solvent 
capacity on 
dispersion 
Loss of 
solvent 
capacity on 
dispersion; 
may not be 
digestible 
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2.1.2.1 Oil/Lipid phase: 
The function of oil phase in self-micro emulsifying 
system is to solubilized the hydrophobic/lipophilic 
active moiety in order to improve both drug loading and 
bioavailability of the hydrophobic active moiety. The 
lipid part of the SMEDDS forms the core of the 
emulsion particle and is typically composed of non-
polar lipids or Class I polar lipids in Small’s Lipid 
Classification system.
27
  
A wide range of lipid excipients are available from 
excipient suppliers. Since these lipids affect the 
absorption process, it is necessary to know the 
characteristics of various excipients
26
. A lipid molecule 
with a large hydrophobic portion compared to 
hydrophilic portion is desirable as it maximizes the 
amount of drug that can be solubilized. The most 
common excipients used in lipid based drug delivery are 
triglyceride vegetable oils. This is one class of lipid 
which does not present any safety issues, since they are 
fully digested and absorbed
26
. Triglycerides can be 
further classified as LCT, MCT and SCT. The capacity 
as a solvent for drugs is mainly decided by the effective 
concentration of ester groups
28
.  
Long chain triglycerides (LCT): 
Lipids that have fatty acid chains of 1420 carbons are 
categorized as LCT
29
. Fixed oils i.e., vegetable oils 
contain a mixture of glyceride esters of unsaturated long 
chain fatty acids. These are considered safe as they are 
commonly present in daily food and are easily digestible 
26
. Large hydrophobic portion of triglycerides is 
responsible for their high solvent capacity for lipophilic 
moieties. Though it is difficult to micro-emulsify, some 
marketed formulations such as Neoral (composed of 
olive oil which, has shown superior oral bioavailability) 
and Topicaine gel (composed of Jojoba oil for 
transdermal application) have been successfully 
practicing the micro-emulsification of LCT
30
. 
Medium chain triglycerides (MCT) and related esters: 
Lipids that have fatty acid chains of 612 carbons are 
categorized as MCT
30
. MCTs are the most common 
choice of oil for SMEDDS as they are resistant to 
oxidation and possess high solvent capacity compared to 
LCT because of their high effective concentration of 
ester group. MCTs produced from the distillation of 
coconut oil are known as glyceryl tricaprylate and 
comprises of saturated C8 and C10 fatty acids in the 
liquid state
26
. Labrafac CM 10, a MCT, has shown 
superior solubility for fenofibrate and produced wider 
microemulsion region at all surfactant/cosurfactant 
combinations than Maisine 35, which, is a LCT
31
. 
Drug substance should possess minimum solubility of 
50 mg/ml in LCTs for lymphatic absorption
32
. Upon 
digestion, products of short and medium chain 
triglycerides are directed towards portal vein whereas 
chylomicrons formed from LCTs triggers the lymphatic 
transport. Further, highly hydrophobic drug substances 
are easily soluble in vegetable oils and can easily be 
formulated as simple oil solutions which are readily 
emulsified in the gut. However, most conventional 
hydrophobic drug substances do not exhibit superior 
solubility in LCT such as vegetable oil
33,34
. 
Moderately hydrophobic drug substances, on the other 
hand, cannot be formulated into simple oil solutions as 
their solubility is limited. In such cases, SMEDDS are 
promising alternative where the drug solubility in the oil 
will be enhanced due to micro emulsification of oil by 
surfactants. It is well accepted that oils with long 
hydrocarbon chains (high molecular volume) such as 
soybean oil, castor oil are difficult to micro-emulsify 
compared to MCT (low molecular volume) such as 
capmul MCM and Miglyol. However, solubilizing 
capacity of oil for lipophilic moiety increases with chain 
length (hydrophobic portion) of the oil. 
Hence the selection of oil is a compromise between the 
solubilizing potential and ability to facilitate the 
formation of microemulsion
35
. Malcolmson et al. 
studied the solubility of testosterone propionate in 
various oils for the formulation of O/W micro-emulsion 
and concluded that oils with larger molecular volume 
such as triglycerides show superior solubility than the 
corresponding micellar solution containing only 
surfactants without oil
36
. Enhancement of drug solubility 
in SMEDDS not only relies on the solubility of the drug 
in the oil but also on the surfactant(s). For instance, 
ethyl butyrate, small molecular volume oil, has shown 
higher solubility for testosterone propionate but its ME 
formulation has only improved the solubility slightly 
than the corresponding micellar solution. On the 
contrary, Miglyol 812 which is a larger molecular 
volume oil has shown improved solubilization in the 
ME formulation though the solubility of testosterone 
propionate is less in the individual components 
compared to ethyl butyrate
36
. The compositions of fatty 
acids found in various lipid excipients are presented in 
Table 3.  
Grovea et al. made a direct comparison of two seocalcitol 
II loaded SMEDDS containing either MCT or LCT. The 
study was performed on monophasic systems with the same 
lipid/surfactant/co-surfactant ratio, which formed 
dispersions with the same droplet size distribution upon 
dilution with the aqueous phase. Cremophor® RH40 was 
used as surfactant in both cases, whereas the co-surfactant 
was chosen to resemble the lipid component in chain 
length. Reportedly, a larger microemulsion area was 
achieved in the phase diagram when MCT was used instead 
of LCT due to the difference in polarity between the lipids. 
As the more hydrophobic LCT is more difficult to 
emulsify, higher concentration of Cremophor® RH 40 was 
generally required to form microemulsions when using 
LCT compared to MCT. Nevertheless, no significant 
differences were observed in the absorption and 
bioavailability of seocalcitol between the two 
aforementioned SMEDDS upon their oral administration to 
male rats 
37
. This is contrary to previous studies, where the 
bioavailability of danazol and halofantrine from SMEDDS 
containing LCT was found to be superior compared to 
SMEDDS containing MCT
38, 39
. However, SMEDDS 
compared in these studies consisted of different amounts of 
lipid and surfactant, whereas Grovea et al. used 
quantitatively comparable systems. Considering the 
mentioned data, one can conclude that the extent of 
influence of MCT and LCT on the bioavailability of drugs 
is drug specific
37
. 
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Table 3: List of oils/lipids used in formulation in SMEDDS 
Class Examples Chracteristics 
T
ri
g
ly
ce
ri
d
es
 
LCT Corn oil, soybean oil, olive oil, 
peanut oil, sesame oil, 
sunflower oil, castor oil, etc. 
1420 carbons in fatty acid chains 
GRAS status, easily ingested, digested, and absorbed, poor self-
dispersing properties of LCT and generally lower loading capacity for 
drugs with intermediate log P values. Their advantage is generally a 
higher solubilizing capacity after dispersion and digestion of the 
formulation 
40-42
. 
MCT Fractionated coconut oil, palm 
seed oil, triglycerides of 
caprylic/ capric acid Miglyol® 
812, Captex® 355 
612 carbons in fatty acid chains 
MCTs exhibit a good solubilizing capacity for less lipophilic drugs 
and good self-dispersing ability. Semisynthetic MCT with 
hydrogenated double bonds are resistant to oxidation 
40-42
. 
Mixed mono-, di- 
and triglycerides 
Imwitor® 988, Imwitor® 308, 
Maisine® 35-1, Peceol® 
Plurol Oleique® CC49, 
Capryol®, Myrj® 
They possess surface active properties because of their amphiphilic 
nature and are effective in replacing conventionally used oils owing to 
their better self-dispersing ability and higher solubilizing capacity for 
poorly water-soluble drugs 
41-41
. 
 
2.1.2.2 Surfactants.  
The self-emulsifying properties require the 
incorporation of relatively large amounts of surfactant in 
the formulation in addition to the oily drug carrier 
vehicle. The surfactants may improve the affinity 
between lipids and intestinal membrane or increase the 
permeability of the intestinal membrane. Surfactants 
increase the permeability by partitioning into the cell 
membrane and disrupting the structural organization of 
the lipid bilayer leading to permeation enhancement
43
. 
Therefore, most drugs are absorbed via the passive 
transcellular route. They also exert their absorption 
enhancing effects by increasing the dissolution rate of 
the drug.  
The selection of surfactant is also critical for the 
formulation of SMEDDS. In order to select a surfactant 
for SMEDDS formulation, due consideration must be 
give to HLB value and safety of surfactant. The HLB of 
a surfactant gives vital information on its application in 
formulation of SMEDDS. The surfactant/emulsifier 
involved in the formulation of SMEDDS should have a 
relatively high HLB and hydrophilicity to enable rapid 
and facile dispersion in the aqueous GI fluid as a very 
fine oil-in-water emulsion, and hence good self-
emulsifying performance can be achieved
44
. The use of 
surfactant blends to achieve the HLB required for 
emulsification has often been proven to provide superior 
self-emulsifying properties relative to the use of a single 
surfactant possessing the desired HLB 
45
.  
Various vegetable oil derivatives like Acrosyl (castor oil 
derivative) are still being found to give optimum self-
emulsification
46
. Nonionic surfactants are normally 
preferred over their ionic counterparts due to lower 
toxicity and greater emulsion stability over a wider 
range of pH and ionic strength. On the other hand, a 
possible disadvantage is their influence on the 
permeability of intestinal lumen with a reversible effect 
43
, further facilitating absorption of the co-administered 
drug. Hydrophobic surfactants can penetrate membranes 
causing changes in membrane fluidity and permeability. 
Safety is a major determining factor in choosing a 
surfactant. Emulsifiers of natural origin (e.g., lecithin, 
Akoline medium chain monoglycerides (MCM), and 
Peceol) are normally preferred since they are considered 
to be safer than the synthetic surfactants. However, these 
excipients have limited self-emulsification efficiency 
41
. 
Generally single alkyl chains are more penetrative, so 
bulky surfactants such as polysorbates and triglyceride 
ethoxylates are found to be less toxic. Usually the 
surfactant concentration ranges between 30 and 60% of 
the total formulation in order to form stable SMEDDS
47
. 
It is very important to determine the surfactant 
concentration properly as large amounts of surfactants 
may cause GI irritation. However, the extremely small 
lipid droplet size produced by SMEDDS formulations 
promotes rapid stomach emptying and wide dispersion 
throughout the GIT, minimizing exposure to high local 
surfactant concentrations and thus reducing the irritation 
potential.  
2.1.2.3 Co-surfactants/Co-solvents  
Usually, the formulation of a successful SMEDDS 
requires high concentrations of surfactant (up to 50%) 
and addition of co-surfactants aids in self-
emulsification. Generally co-surfactant of HLB value 
10-14 is used with surfactant to decrease the oil-water 
interfacial tension, fluidize the hydrocarbon region of 
interfacial film, increase the drug loading to SMEDDS 
and allows the spontaneous formation of micro-
emulsion.
48
 Hence, surfactants (hydrophilic or 
lipophilic) and/or amphiphilic solubilizers are used for 
this purpose. The addition of the co-emulsifiers or 
solubilizers in SMEDDS may result in an expanding 
self-micro-emulsification region in the phase diagrams. 
Organic solvents such as, ethanol, PEG and PG are 
suitable co-solvents for oral delivery, and they enable 
the solubilization of large quantities of either the 
hydrophilic surfactant or the drug in the lipid base. The 
lipid mixture with higher surfactant and co-surfactant: 
oil ratios leading to the formation of SMEDDS
49
. 
Alcohol and other volatile co-solvents have evaporated 
into the shell of soft or hard gelatin capsules, results in 
precipitation of drug. 
2.2 Mechanism of self-emulsification 
Self-emulsification occurs when the entropy change that 
favors dispersion is greater than the energy required to 
increase the surface area of the dispersion. The free 
energy of the conventional emulsion is a direct function 
Maurya et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2017; 7(3):55-65                                     
ISSN: 2250-1177                                                                                [60]                                                                             CODEN (USA): JDDTAO 
of the energy required to create a new surface between 
the water and oil phases and can be described by the 
equation: 
∆G = ∑Ni πri
2
S 
Where ∆G is the free energy associated with the process 
(ignoring the free energy of mixing), N is the number of 
droplets of radius r and S represents the interfacial 
energy. The two phases of emulsion tend to separate 
with time to reduce the interfacial area and, 
subsequently, the emulsion is stabilized by emulsifying 
agents, which form a monolayer of emulsion droplets, 
and hence reduces the interfacial energy, as well as 
providing a barrier to prevent coalescence   Reiss
50, 51
. 
The above equation shows that spontaneous formation 
of interface between oil and aqueous phase is 
thermodynamically stable Reiss 
50
 explained the 
spontaneous formation of emulsion, i.e., self-
emulsification, in terms of the free energy required to 
form the emulsion which is either very low and positive, 
or negative. 
Pouton
52
 has proposed a relationship between the 
emulsification properties of the surfactant and phase 
inversion behavior of the system. For example, the 
temperature of the oil in water system, stabilized by 
using non-ionic surfactant(s) is increased; the cloud 
point of the surfactant would be attained followed by 
phase inversion. The surfactant is highly mobile at the 
phase inversion temperature; hence, the o/w interfacial 
energy is minimized, results to a reduction in energy 
needed for emulsification. 
2.3 Characterizations of SMEDDS 
The various ways to characterize SMEDDS are 
compiled below; 
Visual assessment  
The primary means of self-emulsification assessment is 
visual evaluation. This may provide key information 
about the self emulsifying and micro-emulsifying 
property of the mixture and about the resulting 
dispersion. 
Equilibrium phase diagram 
Comparison of different surfactants and their synergy 
with co-solvent is enabled using equilibrium phase 
diagram. The boundaries of one phase region can easily 
be assessed visually. The phase behavior of a three-
component system can be represented by a ternary phase 
diagram. Phase diagram helps in determining the 
optimum concentrations of different excipients 
necessary to obtain homogenous pre-concentrates, self-
emulsifying ability and drug loading. Each corner of 
phase diagram represents 100% of particular 
components and when more than three components are 
used, closely related one are grouped together as one 
component and treated as such in the diagram.
52
 
Turbidity measurement 
This determines the efficiency of self-emulsification by 
establishing whether the dispersion reaches equilibrium 
rapidly and in a reproducible time 
53
. These 
measurements are carried out using turbidity meters 
(Hach turbidity meter and the Orbeco-Helle turbidity 
meter). 
54
.  
Droplet size 
Microscopic techniques, Photon correlation 
spectroscopy or a Coulter Nanosizer are generally used 
to determine the droplet size of emulsion. Droplet size is 
an important factor in self-emulsification performance 
because it determines the rate and extent of drug release, 
as well as the stability of the microemulsion
55
. 
Electron microscopic studies 
Surface characteristics of micro-emulsion are studied 
using Freeze-fracture electron microscopy
56
.  
Zeta potential measurement 
It is used to identify the charge of the droplets.  
Determination of emulsification time 
This process is used for estimation of the time taken for 
emulsification. In this efficiency of emulsification of 
various compositions of the surfactants and lipids is 
quantified using a rotating paddle to promote 
emulsification in a crude nephelometer
34
. 
Particle size distribution 
Dynamic light scattering techniques is used for 
measurement of particle size distribution of the 
microemulsion. This utilizes the fluctuation in scattered 
light intensity to measure the velocity of the Brownian 
diffusion and consequently the dispersed droplets. 
Particle size distributions can be further verified by 
cryogenic transmission electron microscopy (cryo-
TEM). Cryo-TEM offers the advantage of visualizing 
the particle sizes and shapes.
57
 
Conductivity measurements  
Conductivity measurements are able to determine the 
point of aqueous phase addition where the system 
changes from having oil continuous to a water 
continuous phase. It also helps in monitoring of 
percolation or phase inversion phenomena.
58
 
3 BIOPHARMACEUTICAL ASPECTS OF 
SMEDDS  
These systems increase absorption from the 
gastrointestinal tract by accelerating the dissolution 
process, facilitating the formation of solubilized phases 
by reduction of particle size to the molecular level, 
yielding a solid state solution within the carrier
59
, 
changing drug uptake, efflux and disposition by altering 
enterocyte based transport
60
, and enhancing drug 
transport to the systemic circulation via intestinal 
lymphatic system
61
 
3.1 Effect of Lipids 
The effect of lipids on the bioavailability of orally 
administered drugs is highly complex due to numerous 
mechanisms by which the lipids can alter the 
biopharmaceutical characteristics of the drug. Factors 
such as the acid chain length of triglyceride, the 
saturation degree and the volume of lipid administered 
may affect the drug absorption profile and its 
blood/lymph distribution. 
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Figure 2: Main factors that potentially affect the bioavailability of drugs formulated in SMEDDS 
 
3.1.1 Effect on rate of gastric emptying 
Increase in gastric residence time shows the delivery of 
the drug of it site of action. In particular, it is the lipid 
component of the food that plays a vital role in the 
absorption of lipophilic drugs. Lipids in the GI tract 
provoke delay in gastric emptying, i.e. gastric transit 
time is increased leading to enhanced oral 
bioavailability co-administered lipophilic drug
 67
. 
This can be explained by the ability of a high fat meal to 
stimulate biliary and pancreatic secretions, to decrease 
metabolism and efflux activity, to increase intestinal 
wall permeability, and to a prolongation of GIT 
residence time and transport via lymphatic system
68
. 
Triglycerides and long chain fatty acids play a major 
role in prolonging the GIT residence time. 
3.1.2  Effect on Digestion and solubilization of drug 
The balance between a drug's solubility in the aqueous 
environment of the gastrointestinal lumen and its 
permeation across the lipophilic membrane of 
enterocytes determines its rate and extent of 
absorption
60
. 
Following ingestion, of SMEDDS, gastric lipase 
initiates the digestion of exogenous dietary TG and 
formulation TG. Simultaneously, the mechanical mixing 
(propulsion, grinding and retropulsion) of the stomach 
facilitates formation of a crude emulsion (comprised of 
aqueous gastric fluid and lipid digestion products).  
Later in the small intestine, pancreatic lipase together 
with its cofactor co-lipase203 completes the breakdown 
of TG to diglyceride, monoglyceride and fatty acid. 
Pancreatic lipase acts primarily at the sn-1 and sn-3 
positions of TG to produce 2-monoglyceride and free 
fatty acid
69, 70
. The chemical digestion of formulation- or 
biliary-derived phospholipid (PL) also occurs in the 
small intestine in which pancreatic phospholipase A2 
hydrolyses a single fatty-acid molecule from the sn-2 
position of PL to yield lysophosphatidylcholine and 
fatty acid
71
.  
The presence of exogenous lipids in the small intestine 
also stimulates secretion of endogenous biliary lipids, 
including bile salt (BS), PL and cholesterol from the gall 
bladder. Previously formed monoglycerides, fatty acids, 
and lysophospholipid (products of lipid digestion) are 
subsequently in corporate into a series of colloidal 
structures, including micelles and unilamellar and multi-
lamellar vesicles in the presence of bile salts. The 
solubilization and absorptive capacity of the small 
intestine for lipid digestion products and drugs (D) is 
significantly enhanced due to these formed lipid 
metabolites. In Fig. 3, the oil droplet in the intestine is 
represented in different colors to indicate undigested TG 
in the core (orange) and digested products such as fatty 
acid (blue) and monoglyceride (green) on the surface of 
the droplet.  
 
Figure 3: Lipid digestion and drug solubilization process in the small intestine
72
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Following their penetration through the aqueous layer 
and mucin, mixed micelles and micro-emulsions are 
absorbed either by pinocytosis, diffusion or endocytosis. 
The drug compound then reaches the systemic 
circulation via the portal vein or lymphatic system 
3.1.3 Promotion of intestinal lymphatic transport 
For highly lipophilic drugs, lipids may enhance the 
extent of lymphatic transport and increase 
bioavailability directly or indirectly via a reduction in 
first‐pass metabolism 62-64. Lipids increase the TG-rich 
lipoproteins which react with drug molecules. 
Lipoproteins-drug complex enhances intestinal 
lymphatic transport and leads to changes in drug 
disposition and finally changes the kinetics of the 
pharmacological actions of poorly soluble drugs
73
.  
The effect of structured triglycerides with varying intra 
molecular structures and chain lengths incorporated into 
a SMEDDS on the intestinal lymphatic transport and 
absorption of halofantrine into the blood was 
investigated 
74
. The SMEDDS formulation included 
29% w/w structured triglyceride designated as LLL, 
LML, or MLM (L: long chain fatty acid, C18; M: 
medium chain fatty acid, C8-10). The MLM and LML 
micro-emulsions had a similar droplet size of 50 nm. 
The lymphatic transport of halofantrine, expressed as 
the cumulative percentage of the administered dose, 
after 12 h (mean % dose ± S.E.) was 27.4 ± 1.3 after 
administration in the LML and 17.9 ± 1.3 in the MLM. 
The results indicated that the structural formation of the 
triglyceride initiated a lymphatic transport at a high 
level. It was therefore hypothesized that medium chain 
fatty acid enhanced the absorption into the systemic 
blood circulation whereas long chain fatty acid 
enhanced the lymphatic transport. Thus, the absorption 
profile of a drug formulated into a SMEDDS could be 
manipulated by varying the medium and long chain 
triglyceride content in the formulation in order to 
improve the oral bioavailability of highly lipophilic 
drugs. 
3.1.4 Effect on intestinal permeability 
Oil component alters the solubility of the drug in 
SMEDDS by penetrating into the hydrophobic portion 
of the surfactant monolayer. Extent of oil penetration 
varies and depends on the molecular volume, polarity, 
size and shape of the oil molecule. Overall drug 
solubility in SMEDDS is always higher than the 
solubility of drug in individual excipients that combine 
to form SMEDDS. However, such higher solubility 
considerably depends on the solubility of drug in oil 
phase, interfacial locus of the drug and drug-surfactant 
interactions at the interface
75
.  
In light scattering experiments, it was observed that oils 
with small molecular volume act like co-surfactants and 
penetrate into the surfactant monolayer. This forms 
thinner polyoxyethylene chains near the hydrophobic 
core of the micelle disrupting the main locus of the drug 
solubilization due to which, a higher solubility of drug is 
not observed.  
Large molecular volume oils, however, forms a distinct 
core and do not penetrate effectively into the surfactant 
monolayer. The locus of drug solubilization was found 
to be effected by the microstructure and solubility of the 
drug in the excipients. The locus of drug solubilization 
was found to be at the interface of micelle for 
phytosterols whereas the same for cholesterol was found 
to be between the hydrophobic head groups of surfactant 
molecules. This is attributed to altered side chain 
flexibility of phytosterol due to the additional 
substitution of alkyl side chain compared to 
cholesterol
76
. 
In addition to molecular volume and polarity of the oil, 
drug solubility in oil is affected by physicochemical 
properties of drug molecule itself. Consideration of BCS 
classification and Lipinski's rule of 5 for the selection of 
drug is only useful during initial screening stages. As 
per BCS classification, some of the acidic drugs are 
listed in Class II despite having good absorption and 
disposition as they do not satisfy the requirement of 
higher solubility at low pH values. Lipinski's rule of 5, 
on the other hand, holds good only when the drug is not 
a substrate for the active transporter
77
. This suggests that 
aqueous solubility and log P alone are not sufficient to 
predict the solubility of drug in the oil. This further 
indicates that the solubility of any two drugs with 
similar log P would not be the same due to their 
different physicochemical properties. 
3.1.5 Reduced metabolism and efflux activity 
In some cases, as shown recently, excipients 
incorporated in SMEDDS can inhibit both pre-systemic 
drug metabolism and intestinal efflux mediated by P-gp 
resulting in an increased oral absorption of cytotoxic 
drugs 
65-66
. It is clear that certain lipids and surfactants 
may attenuate the activity of intestinal efflux 
transporters, as indicated by the p-glycoprotein efflux 
pump, and may also reduce the extent of 
enterocyte‐based metabolism 65, 78. Therefore uptake of 
lipophilic drugs formulated as SMEDDS from the GI 
tract can enhanced due to decrease in the P-gp drug 
efflux
79
. In addition to a multidrug efflux pump, phase I 
metabolism by the intestinal Cytochrome P450s is now 
becoming recognized as a significant factor in oral drug 
bioavailability.
80
 
3.2 Effect of surfactants 
3.2.1 Effects on permeability 
Surfactants increase the permeability by interfering with 
the lipid bilayer of the single layer of the epithelial cell 
membrane 
81
, which with the unstirred aqueous layer, 
forms the rate-limiting barrier to drug 
absorption/diffusion
62
. Therefore, most drugs are 
absorbed via the passive transcellular route. Surfactants 
partition into the cell membrane and disrupt the 
structural organization of the lipid bilayer leading to 
permeation enhancement. They also exert their 
absorption enhancing effects by increasing the 
dissolution rate of the drug
83
. They also exert their 
absorption enhancing effects by increasing the 
dissolution rate of the drug
84
.  
3.2.2 Effect on Droplets size 
The lipid mixtures with higher surfactant and co-
surfactant/oil ratios lead to the formation of SMEDDS 
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85
. The surfactant concentration required to form a stable 
SMEDDS ranges from 30 to 60 % (m/m) 
86
. The lowest 
possible surfactant concentration should be used in order 
to prevent gastric irritation. The extremely small droplet 
size produced in the case of SMEDDS promotes rapid 
gastric emptying and low local concentration of the 
surfactant, thereby reducing gastric irritation. 
There is a relationship between the droplet size and the 
concentration of the surfactant being used. Surfactant 
concentration has been shown to have varying effects on 
the droplet size of emulsion. Increase in surfactant 
concentration causes a decrease in droplet size 
associated with stabilization of surfactant molecules at 
the oil-water interface, although the reverse is possible 
due to enhanced water penetration into oil droplets 
leading to their breakdown 
43
. 
In some cases, increasing the surfactant concentration 
could lead to droplets with smaller mean droplet size 
such as in the case of a mixture of saturated C8-C10 
polyglycolized glycerides (Labrafac CM-10). This could 
be explained by the stabilization of the oil droplets as a 
result of the localization of the surfactant molecules at 
the oil-water interface 
87
. On the other hand, in some 
cases the mean droplet size may increase with increasing 
surfactant concentrations 
88
. This phenomenon could be 
attributed to the interfacial disruption elicited by 
enhanced water penetration into the oil droplets 
mediated by the increased surfactant concentration and 
leading to ejection of oil droplets into the aqueous 
phase.  
The role of surfactants in SMEDDS is to reduce the 
interfacial tension and adjust the spontaneous curvature 
of the interface so as to enable the dispersion process 
and provide a flexible film that can easily cover the lipid 
core of the emulsion droplets and lead to the 
spontaneous formation of a nano- or micro-emulsion. 
Basically, the increase of surfactant activity at the 
water–oil interface would result in a decrease of 
interfacial tension. Moreover, the addition of a second 
surfactant to the system would usually cause a further 
decrease in interfacial tension down to a very small, 
even transient negative value, at which the interface 
would expand to form fine dispersed droplets.  
4. CONCLUSION 
Lipid-based drug delivery systems, especially 
SMEDDS, are a promising approach for improving the 
bioavailability of poorly soluble drug. Bioavailability 
enhancement have been attributed to a number of 
factors, including delivery of the drug in solution to the 
gastrointestinal tract, increased bile secretion, easier 
partition of the drug into the mixed micelles that are 
believed to facilitate drug absorption, stimulation of 
gastric lymphatic transport and increased intestinal 
permeability.  
The effect of lipids on the bioavailability of orally 
administered drugs is highly complex due to numerous 
mechanisms by which the lipids can alter the 
biopharmaceutical characteristics of the drug. Better 
understanding of the role of individual lipids, surfactants 
and co-surfactants in the formation of SMEDDS, with 
regard to the dispersion process, the structure of the 
formed emulsion particle and drug solubilisation is very 
important in successful designing of these formulations. 
Therefore this review focused on the physic-chemical 
and biopharmaceutical aspects of the SMEDDS which 
may be helpful for the advancement of this technology 
to obtain a safer, more stable and efficacious SMEDDS 
formulations.
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Abbreviations: 
SMEDDS: self-micro emulsified drug delivery system 
SEDDS: Self-emulsifying drug delivery systems  
LFCS: Lipid formulation classification system  
MCM: Medium chain monoglycerides  
GI: gastrointestinal  
HPMC: hydroxypropyl methylcellulose 
P-gp: P-glycoprotein  
GRAS: Generally Recognized as Safe 
HLB: hydrophilic-lipophilic balance  
MCT: medium-chain triglyceride 
LCT: long-chain triglyceride 
PEG: polyethylene glycol  
TG: Triglyceride  
BCS: Biopharmaceutical classification system
 
